BARINTHUS BIOTHERAPEUTICS PL

BRNSNASDAQ

🏆 #3799 by market capEarnings Nov 5US Equity

$0.60▼ $0.01 (−1.01%)

Market closed · at close

1h—

24h▼ 1.0%

7d▲ 0.0%

14d▼ 1.0%

30d▼ 1.7%

1y▼ 53.1%

🏦Market Cap

$25M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

1.6x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $0.60 – $0.60
52-Week Range: $0.51 – $1.83
Volume: $2.36B
Avg Volume: $2.20B
Shares Outstanding: 40.9M
Next Earnings: Oct 9, 2026

Fundamentals Snapshot

Annual Revenue: $14M
Last Q Revenue: $3M
P/E Ratio: —
P/S Ratio: 1.6x
EPS (TTM): $-1.12
Dividend Yield: —

Why Investors Own BRNS

✓High-growth profile — revenue up +43.9% YoY with expanding US Equity exposure.
✓Healthy economics — 35% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$14M▲ +39.9% YoY

Gross Margin (TTM)

35.4%▲ +1.7% YoY

Operating Income (TTM)

$1M▲ +39.9% YoY

Free Cash Flow (TTM)

$2M▲ +39.9% YoY

About BARINTHUS BIOTHERAPEUTICS PL

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.

🦦